Insider Selling: Danaher Co. (NYSE:DHR) SVP Sells $5,371,846.38 in Stock

Danaher Co. (NYSE:DHR) SVP William King sold 26,982 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $199.09, for a total value of $5,371,846.38. Following the transaction, the senior vice president now directly owns 29,821 shares of the company’s stock, valued at $5,937,062.89. The sale was disclosed in a filing with the SEC, which is available at this link.

DHR opened at $203.80 on Friday. The stock has a market cap of $142.15 billion, a P/E ratio of 43.64, a P/E/G ratio of 3.24 and a beta of 0.92. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.20 and a quick ratio of 1.74. The stock’s 50 day simple moving average is $182.24 and its 200 day simple moving average is $161.95. Danaher Co. has a 1-year low of $119.60 and a 1-year high of $204.13.

Danaher (NYSE:DHR) last announced its earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.35. The firm had revenue of $5.30 billion for the quarter, compared to analysts’ expectations of $5.01 billion. Danaher had a return on equity of 11.88% and a net margin of 17.73%. Danaher’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.09 EPS. Research analysts expect that Danaher Co. will post 5.36 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Friday, June 26th were issued a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date was Thursday, June 25th. Danaher’s dividend payout ratio (DPR) is presently 16.29%.

A number of large investors have recently made changes to their positions in DHR. Lion Street Advisors LLC acquired a new stake in Danaher during the 1st quarter valued at $25,000. Archer Investment Corp acquired a new stake in Danaher during the 4th quarter valued at $27,000. Howe & Rusling Inc. grew its holdings in Danaher by 81.4% during the 2nd quarter. Howe & Rusling Inc. now owns 156 shares of the conglomerate’s stock valued at $28,000 after buying an additional 70 shares during the last quarter. Manchester Financial Inc. grew its holdings in Danaher by 50.0% during the 1st quarter. Manchester Financial Inc. now owns 228 shares of the conglomerate’s stock valued at $32,000 after buying an additional 76 shares during the last quarter. Finally, Semmax Financial Advisors Inc. acquired a new stake in Danaher during the 2nd quarter valued at $35,000. Hedge funds and other institutional investors own 77.67% of the company’s stock.

A number of brokerages have recently issued reports on DHR. Jefferies Financial Group increased their target price on Danaher from $190.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Needham & Company LLC increased their target price on Danaher from $183.00 to $209.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Citigroup increased their target price on Danaher from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $195.00 target price for the company in a research note on Tuesday, June 16th. Finally, Royal Bank of Canada increased their target price on Danaher from $205.00 to $218.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $197.73.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Further Reading: Trading based on a resistance level

Insider Buying and Selling by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.